8-K: Moleculin Biotech Receives Favorable FDA Feedback for Pediatric Annamycin Study in R/R AML

Moleculin Biotech, Inc. announced positive feedback from the FDA on its Initial Pediatric Study Plan for Annamycin, allowing for a single pediatric approval study in children as young as 6 months with relapsed/refractory acute myeloid leukemia.

Summary

• Moleculin Biotech received positive written feedback from the U.S. Food and Drug Administration (FDA) regarding its Initial Pediatric Study Plan (iPSP) for Annamycin (AnnAraC) in pediatric patients with relapsed/refractory acute myeloid leukemia (R/R AML).
• The FDA agreed to a single pediatric approval study for Annamycin in combination with Cytarabine (AnnAraC) as second-line therapy.
• The FDA recommended including patients as young as 6 months, expanding from Moleculin's proposed 2-16 years age range, and clarified that comparable drug concentration exposure and safety profile could allow extrapolation of efficacy from adult data.
• Importantly, the FDA stated that Moleculin would be able to start the pediatric trial before having the full two years of follow-up data from the adult trial.
• Moleculin is updating its iPSP to incorporate FDA recommendations and intends to submit the revised plan later this quarter, with the initiation of the pediatric clinical study expected in the second half of 2027.
• The pivotal, adaptive Phase 3 MIRACLE trial for AnnAraC in adult R/R AML patients is ongoing, with initial data readout on track for the second half of 2025.
• Annamycin has shown no cardiotoxicity to date in 84 adult patients, addressing a major concern with current anthracycline treatments used in about 60% of pediatric cancer cases.
• Annamycin has been granted Fast Track Status and Orphan Drug Designation by the FDA for R/R AML and soft tissue sarcoma, and Orphan Drug Designation by the European Medicines Agency (EMA) for R/R AML.

Sentiment

Score: 8

Explanation: The FDA feedback is highly positive, streamlining the pediatric development pathway and expanding the potential patient population. The lack of cardiotoxicity is a significant advantage. The main caveat is the explicit mention of the need for significant additional financing without commitments, which is a common risk for clinical-stage biotech companies.

Positives

• The FDA agreed to a single pediatric approval study for Annamycin in R/R AML, streamlining the development pathway.
• The FDA recommended including patients as young as 6 months, expanding the potential patient population beyond the company's initial proposal of 2-16 years.
• The FDA indicated that comparable drug concentration exposure and safety profile could allow extrapolation of efficacy from adult data, potentially reducing the burden of pediatric trials.
• Moleculin can start the pediatric trial before the full two years of follow-up data from the adult trial is available, potentially accelerating the pediatric development timeline.
• Annamycin has demonstrated no cardiotoxicity in 84 adult patients, a significant advantage over currently prescribed anthracyclines which cause heart damage in about 60% of pediatric cancer patients.
• Annamycin holds FDA Fast Track Status and Orphan Drug Designations (for R/R AML and soft tissue sarcoma) and EMA Orphan Drug Designation (for R/R AML), indicating regulatory support and potential market exclusivity benefits.
• The adult Phase 3 MIRACLE trial is on track for initial data readout in the second half of 2025.

Risks

• Moleculin will require significant additional financing to conduct its clinical trials, for which the Company has no commitments.
• The milestones described in the press release assume the Company's ability to secure such financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results due to known and unknown risks, uncertainties, and other factors.
• Risks are discussed under Item 1A. Risk Factors in the company's most recently filed Form 10-K and updated in Form 10-Q filings and other public SEC filings.

Future Outlook

Moleculin expects to submit its revised Initial Pediatric Study Plan (iPSP) to the FDA later this quarter and initiate the pediatric clinical study in the second half of 2027. The initial data readout for the pivotal Phase 3 MIRACLE trial in adult R/R AML patients is on track for the second half of 2025.

Management Comments

• "We continue to be encouraged by the potential of Annamycin to change the game when it comes to the most prevalent cancer therapies in use today. This is particularly important in pediatric oncology, where about 60% of children with cancer are treated with anthracyclines that present a high risk of causing heart damage." Walter Klemp, Chairman and CEO of Moleculin.
• "An independent expert’s review of study data has shown no cardiotoxicity to date in 84 adult patients treated with Annamycin, which is why we’re excited about moving forward in young children with cancer." Walter Klemp.
• "Receiving this written feedback from FDA is a crucial step in the development of Annamycin for pediatric use and provides us with helpful insight as we continue to prepare for the launch of a pediatric trial, planned for the second half of 2027." Walter Klemp.
• "As our team works to address and implement FDA’s feedback on our iPSP, we remain focused on the successful execution of our ongoing MIRACLE trial of AnnAraC in adult patients with R/R AML and look forward to initial data from that trial later this year." Walter Klemp.

Industry Context

This announcement highlights Moleculin's focus on addressing a critical unmet need in pediatric oncology: the cardiotoxicity associated with conventional anthracycline chemotherapy, which is used in a significant portion (60%) of pediatric cancer cases. Annamycin's design to avoid multidrug resistance and eliminate cardiotoxicity positions it as a potentially safer and more effective alternative in the highly sensitive pediatric population, a significant advancement in the field of AML treatment.

Comparison to Industry Standards

• Annamycin is designed to eliminate cardiotoxicity common with currently prescribed anthracyclines, which present a high risk of causing heart damage in about 60% of children with cancer.
• Preclinical studies have demonstrated Annamycin lacks cardiotoxicity as compared to a currently prescribed anthracycline.
• An independent expert's conclusions after analyzing data from 84 subjects treated with Annamycin in five clinical studies conducted in the US and Europe showed no cardiotoxicity to date, differentiating it from standard anthracycline treatments.

Stakeholder Impact

• Shareholders: Positive regulatory news and progress in clinical trials could increase investor confidence and potentially share price, but the explicit mention of the need for future financing poses a potential dilution risk.
• Patients (Pediatric R/R AML): Potential for a new, less cardiotoxic treatment option, especially for very young children (6 months and older), addressing a critical unmet medical need.
• Employees: Continued progress in drug development provides stability and potential for growth within the company.
• Healthcare Providers: A new treatment option for a difficult-to-treat cancer with a potentially better safety profile could improve patient outcomes and expand therapeutic choices.

Next Steps

• Moleculin to update its Initial Pediatric Study Plan (iPSP) to incorporate FDA recommendations.
• Submit the revised iPSP to the FDA later this quarter.
• Initiate pediatric clinical study in the second half of 2027.
• Continue enrollment and dosing in the pivotal Phase 3 MIRACLE trial for adult R/R AML patients.
• Anticipate initial data readout from the adult MIRACLE trial in the second half of 2025.

Key Dates

Recommendation

Keywords

Moleculin Biotech, Annamycin, naxtarubicin, AnnAraC, Cytarabine, Ara-C, relapsed/refractory acute myeloid leukemia, R/R AML, pediatric oncology, cardiotoxicity, anthracyclines, FDA, Initial Pediatric Study Plan, iPSP, MIRACLE trial, Phase 3, Orphan Drug Designation, Fast Track Status, cancer treatment, pharmaceuticals, clinical trial, oncology